Alirocumab's ODYSSEY continues into once-monthly dosing territory
This article was originally published in Scrip
Sanofi and Regeneron have announced positive top-line Phase III data for their investigational PCSK9 inhibitor alirocumab when dosed every four weeks, narrowing what little gap there was between it and its main rival Amgen's evolocumab.
You may also be interested in...
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.